In this article, we aimed to characterize the effects of three inhibitors of the PI3K/AKT/mTOR pathway (TAK‐228, everolimus and TAK‐117) on the regulation and function of the PD‐1/PD‐L1 pathway in BC models and to explore whether the effects of the mTOR pathway inhibition in cancer cells may affect the anti‐tumor immune responses. Here, PDCD1 is linked to cancer.